Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

16.32USD
4:00pm EDT
Change (% chg)

$0.04 (+0.25%)
Prev Close
$16.28
Open
$16.32
Day's High
$16.61
Day's Low
$16.18
Volume
408,610
Avg. Vol
274,686
52-wk High
$18.83
52-wk Low
$13.24

Latest Key Developments (Source: Significant Developments)

Halozyme Therapeutics Expects To Announce Top Line Results For HALO-301 Clinical Trial By December
Wednesday, 12 Jun 2019 02:23pm EDT 

June 12 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME THERAPEUTICS INC SAYS REACHED TARGET NUMBER OF 330 OVERALL SURVIVAL EVENTS IN ITS HALO-301 CLINICAL TRIAL - SEC FILING.HALOZYME - PLANS TO CONDUCT FINAL OVERALL SURVIVAL ANALYSIS IN HALO-301 CLINICAL TRIAL UPON DATA MATURITY WHICH CO PROJECTS TO ACHIEVE IN MID-SEPT.HALOZYME THERAPEUTICS INC - EXPECTS TO ANNOUNCE TOP LINE RESULTS FOR HALO-301 CLINICAL TRIAL BY DECEMBER 2019.  Full Article

argenx Has Selected Second Target Under ENHANZE Technology Collaboration And License Agreement
Wednesday, 22 May 2019 01:05am EDT 

May 22 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME ANNOUNCES ARGENX HAS SELECTED SECOND TARGET UNDER ENHANZE® TECHNOLOGY COLLABORATION AND LICENSE AGREEMENT.HALOZYME WILL RECEIVE A $10 MILLION MILESTONE PAYMENT DURING CURRENT QUARTER FROM ARGENX FOR THIS TARGET NOMINATION.HALOZYME THERAPEUTICS- RECEIVE POTENTIAL FUTURE PAYMENTS OF UP TO $160 MILLION SUBJECT TO ACHIEVEMENT OF SPECIFIED DEVELOPMENT, REGULATORY, SALES-BASED MILESTONES.HALOZYME WILL ALSO RECEIVE MID-SINGLE DIGIT ROYALTIES ON FUTURE COMMERCIAL SALES PRODUCTS.  Full Article

Halozyme Provides 2019 Pipeline Update And Financial Guidance
Wednesday, 9 Jan 2019 01:30pm EST 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROVIDES 2019 PIPELINE UPDATE AND FINANCIAL GUIDANCE AT 37TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE.SEES FY 2019 REVENUE $175 MILLION TO $185 MILLION.HALOZYME THERAPEUTICS - ANTICIPATED ENHANZE PARTNER PROGRESS IN 2019 INCLUDES 1 FDA APPROVAL, NEW REGULATORY SUBMISSIONS AND A NEW PHASE 3 INITIATION.SEES 2019 OPERATING EXPENSES OF $265 MILLION TO $275 MILLION.SEES 2019 OPERATING CASH BURN OF $75 MILLION TO $85 MILLION.PROJECTS TOPLINE RESULTS FROM PEGPH20 STUDY WILL BE AVAILABLE IN SECOND HALF OF 2019..SEES 2019 YEAR-END CASH BALANCE OF $180 MILLION TO $190 MILLION.FY2019 REVENUE VIEW $152.6 MILLION -- REFINITIV IBES DATA.HALOZYME THERAPEUTICS - EXPECTS TO MAKE MEANINGFUL PROGRESS IN 2019 TOWARD ITS PROJECTION OF POTENTIAL FOR ABOUT $1 BILLION IN ROYALTY REVENUE IN 2027.IN SECOND HALF, EXPECTS A PHASE 3 STUDY WILL BE INITIATED BY A PARTNER FOR AN UNDISCLOSED TARGET.BY END OF 2019, EXPECTS THREE ENHANZE PROGRAMS TO BE IN PHASE 3 STUDIES.  Full Article

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of Bms-986179 With Enhanze Technology
Thursday, 25 Oct 2018 08:00am EDT 

Oct 25 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME ANNOUNCES FIRST CLINICAL DOSING IN BRISTOL-MYERS SQUIBB'S PHASE 1 TRIAL OF BMS-986179 WITH ENHANZE® TECHNOLOGY.HALOZYME - INITIATION OF STUDY TRIGGERED A $5 MILLION MILESTONE PAYMENT TO HALOZYME UNDER COLLABORATION AND LICENSE AGREEMENT BETWEEN COMPANIES.  Full Article

Halozyme Therapeutics Q2 Loss Per Share $0.16
Tuesday, 7 Aug 2018 04:21pm EDT 

Halozyme Therapeutics Inc ::HALOZYME REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.16.Q2 REVENUE $35.2 MILLION VERSUS I/B/E/S VIEW $30.1 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.ACHIEVEMENT OF TARGET NUMBER OF PROGRESSION-FREE SURVIVAL EVENTS IN HALO-301 ON TRACK FOR DECEMBER 2018 TO FEBRUARY 2019.SEES 2018 NET REVENUE $125 MILLION TO $135 MILLION.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 06:30pm EST 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Halozyme reports Q3 EPS of $0.02
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Halozyme Therapeutics Inc :Halozyme reports third quarter 2017 results.Q3 earnings per share $0.02.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q3 revenue $63.7 million versus i/b/e/s view $59 million.Sees FY 2017 ‍net revenue of $265 million to $280 million​.Qtrly ‍ cash, cash equivalents & marketable securities were $316.9 million at Sept. 30, 2017, versus $297.5 million at June 30, 2017​.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article